FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 309:816-821 October 6, 1983 Number 14 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Type IIB von Willebrand's disease is a distinct form of this disorder, in which there are abnormal factor VIII/von Willebrand factor multimers in plasma (but normal multimers in platelets) and heightened interaction between the von Willebrand factor and platelets in the presence of ristocetin. We have found that infusion of desmopressin acetate (1-desamino-8-D-arginine vasopressin [DDAVP]), an agent used in the treatment of von Willebrand's disease, causes platelet aggregation and thrombocytopenia in patients with Type IIB disease. In vitro, platelets in normal plasma and those obtained from patients with Type IIB disease before DDAVP infusion aggregated upon the addition of platelet-poor plasma from Type IIB patients treated with DDAVP. Platelet aggregation was associated with adsorption of multimers of factor VIII/von Willebrand factor onto the platelets and was inhibited by EDTA. We conclude that in Type IIB von Willebrand's disease, DDAVP releases an abnormal factor with platelet-aggregating properties. DDAVP should not be used to treat patients with Type IIB disease, since the presence of platelet aggregates in the circulation may be harmful.

This article has been cited by other articles:

• Mannucci, P. M. (2004). Treatment of von Willebrand's Disease. NEJM 351: 683-694 [Full Text]  
• Federici, A. B., Mazurier, C., Berntorp, E., Lee, C. A., Scharrer, I., Goudemand, J., Lethagen, S., Nitu, I., Ludwig, G., Hilbert, L., Mannucci, P. M. (2004). Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 103: 2032-2038 [Abstract] [Full Text]  
• Mannucci, P. M. (2001). How I treat patients with von Willebrand disease. Blood 97: 1915-1919 [Abstract] [Full Text]  
• Pareti, F. I., Lattuada, A., Bressi, C., Zanobini, M., Sala, A., Steffan, A., Ruggeri, Z. M. (2000). Proteolysis of von Willebrand Factor and Shear Stress-Induced Platelet Aggregation in Patients With Aortic Valve Stenosis. Circulation 102: 1290-1295 [Abstract] [Full Text]  
• Allen, G. C., Armfield, D. R., Bontempo, F. A., Kingsley, L. A., Goldstein, N. A., Post, J. C. (1999). Adenotonsillectomy in Children With von Willebrand Disease. Arch Otolaryngol Head Neck Surg 125: 547-551 [Abstract] [Full Text]  
• Mauz-Körholz, C, Budde, U, Kruck, H, Körholz, D, Göbel, U (1998). Management of severe chronic thrombocytopenia in von Willebrand's disease type 2B. Arch. Dis. Child. 78: 257-260 [Abstract] [Full Text]  
• Mannucci, P. M. (1997). Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. Blood 90: 2515-2521 [Full Text]